EcoDrugPlus

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Beta

Ensembl ID : ENSDCDG00000021024
Gene Symbol: PIK3CB
3 Cross references
218 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta

Ensembl ID : ENSDCDG00000024282
Gene Symbol: PIK3CD
3 Cross references
214 Possible Orthologues:

Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma

Ensembl ID : ENSDCDG00000030311
Gene Symbol: PIK3CG
3 Cross references
216 Possible Orthologues:

Phosphodiesterase 10a

Ensembl ID : ENSDCDG00000011532
Gene Symbol: PDE10A
3 Cross references
207 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSDCDG00000026646
Gene Symbol: PDE3A
3 Cross references
202 Possible Orthologues:

Phosphodiesterase 3a

Ensembl ID : ENSDCDG00000007111
Gene Symbol: PDE3A
3 Cross references
186 Possible Orthologues:

Phosphodiesterase 3b

Ensembl ID : ENSDCDG00000009980
Gene Symbol: PDE3B
3 Cross references
204 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSDCDG00000023198
Gene Symbol: PDE4A
3 Cross references
187 Possible Orthologues:

Phosphodiesterase 4a

Ensembl ID : ENSDCDG00000023977
Gene Symbol: PDE4A
3 Cross references
180 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSDCDG00000034434
Gene Symbol: PDE4B
3 Cross references
229 Possible Orthologues:

Phosphodiesterase 4b

Ensembl ID : ENSDCDG00000002588
Gene Symbol: PDE4B
3 Cross references
224 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSDCDG00000029029
Gene Symbol: PDE4D
3 Cross references
222 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).